Advertisement
Advertisement
U.S. Markets close in 5 hrs 35 mins
Advertisement
Advertisement
Advertisement
Advertisement

89bio, Inc. (ETNB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.61+0.15 (+2.75%)
As of 10:24AM EDT. Market open.
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • L
    Lars
    Wow, solitary green light in a sea of red. Must have been good news and deep pockets at the H.C. Wainwright conference.
  • R
    Redposition
    89bio stock price target raised to $25 from $14 at Raymond James
    Sep. 14, 2022 at 6:02 a.m. ET by Tomi Kilgore
  • K
    Kuryo193
    Dreaming of those green days 🤞🏼
  • I
    Isaac
    wow
  • a
    alan
    some nice blocks before the close ..
  • s
    silver
    Looking good today. On the way to $20?
    Bullish
  • K
    Kuryo193
    “89bio Presents Positive Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at European Society of Cardiology Congress 2022”

    Letsgoooooo 🚀
    Bullish
  • G
    G.Growl
    Phase 2B trial filled up quickly and results will be coming in early 2023
    Trials fill quickly when Doctors are impressed by a drug and guide their patients into a trial. A triple in 2023?

    Akero has a drug in the same class and announced impressive phase II results. 89bio likely has the DOC in this field.
  • E
    Edelstein
    (DERM) $3 ...MC $51 m / Cash $38 m / Revenue $70 m ..has 9x Products on Marketed and many others to follow soon =unknown gem with 1000% opportunityy
  • W
    Watertown Advisor
    This stock was up more than 30% in one day and now people are dumping it like trash. They are either doing well with their phase 2 trial or not. If they are, the stock should be rising. Can someone who has been following this please explain?
  • R
    Rks
    Keep growing my beautiful cheap stock
  • d
    diana
    HC Wainwright remains confident in a robustly positive readout based on the positive topline results from the 13-week Phase 1b study.
    The analyst raised the price target from $26 to $27 with a Buy rating.
  • R
    Rks
    Wow this stock really took a tumble in the last week
  • B
    Brannon
    Good lawd who is excited??????
    Bullish
  • G
    G
    who would buy this when ndx is -4.6%
  • W
    Watertown Advisor
    If they are starting to get FDA approvals and things are going well, then how come the insiders and company officers are not buying the stock at this low price? It seems odd to meet that if they thought it was worth $21 a year ago, that $5 wouldn't be a good entry point. Does anyone else think this is strange?
  • R
    Rks
    Very quietly having a nice day and will continue on!
  • H
    Horowitz
    (EYEN) $2.30 has 3x BIG PHASE 3 Drugs with data readout coming within days =1000% opportunity
  • S
    Steven
    what did they say at the conference? yikes!
  • B
    Brannon
    Anyone know why the drop today? Thinking just some profit taking
    Bullish
Advertisement
Advertisement